- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02519582
Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy (Nikolo)
September 11, 2018 updated by: Susen Burock, Charite University, Berlin, Germany
Phase II Trial to Investigate the Safety and Efficacy of Orally Applied Niclosamide in Patients With Metachronous or Synchronous Metastases of a Colorectal Cancer Progressing After Therapy
Phase II trial evaluating the safety and efficacy of oral appliqued niclosamide in patients who are progressive with metachronous or synchronous metastases of colorectal cancer among the previous therapy (Nikolo).
Monocentric open-label clinical trial of phase II.
All patients received 2 g p.o. niclosamide daily until progression (according to RECIST) or unacceptable toxicity or discontinuation of study for other reasons.
Study Overview
Detailed Description
Effectiveness:
• effectiveness is measured by progression-free survival evaluated by RECIST (Response Evaluation Criteria In Solid tumor).
Overall survival For overall survival, the curves are estimated using the Kaplan-Meier method
Study Type
Interventional
Enrollment (Anticipated)
37
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Susen Burock
- Phone Number: 0049 (0)30450564648
- Email: susen.burock@charite.de
Study Locations
-
-
-
Berlin, Germany, 10117
- Recruiting
- Charité Universitätsmedizin Berlin; Charité Comprehensive Cancer Center
-
Contact:
- Susen Burock
- Phone Number: 0049(0)30450564648
- Email: susen.burock@charite.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient with metachronous or synchronous metastases of a colorectal cancer progression under standard therapy
- no proven brain metastases
- no curative option
- no standard therapy available
- Age > 18 years
- At least one metastases measurable according to Response Evaluation Criteria In Solid Tumors V 1.1 in CT or MRI scan not older than 2 weeks before inclusion into the trial
- Lab values within the usual borders for these patient group e.g.
- Neutrophil ≥ 1.5x109/ •Platelets ≥ 100x109/L
- Leukocytes ≥ 1.0x109/L
- Hemoglobin ≥ 9.0 g/dL or 5.59 mmol/l
- Bilirubin ≤ 2 x Upper Limit of Normal (ULN) if not due to Gilbert's syndrome
- Aspartate Aminotransferase ≤ 2.5x Upper Limit of Normal in patients without liver metastases or ≤ 5.0x Upper Limit of Normal in patients with liver metastases
- Alanine aminotransferase ≤ 2.5x Upper Limit of Normal in patients without liver metastases < 5.0 x Upper Limit of Normal in patients with liver metastases
- adequate renal function (creatinin ≤ 1.5x Upper Limit of Normal)
- Eastern Cooperative Oncology Group 0 - 1
- EKG without clinical significant abnormalities
- No other malignant disease (except colorectal cancer) within the last 5 years before inclusion in the trial except adequately treated basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ carcinoma of the cervix. Patients with a malignant disease in history have to be free of disease for 5 years.
- No clinical significant heart disease like e.g.
- Uncontrolled blood pressure
- Heart failure New York Heart Association grade > 2
- Cardiac infarction within the last 12 months
- No known uncontrolled concomitant disease despite treatment like e.g.
- Chronic obstructive pulmonary disease (COPD)
- Serious infections
- No known alcohol or drug abuses
- Absence of any psychological, familial, sociological or geographical condition, potentially hampering compliance with the study protocol and follow-up schedule
- Patients should use adequate birth control measures, during the study treatment period and for at least 3 months after the last study treatment.
- For women of childbearing potential (WOCBP):negative pregnancy test 72 hours before the application of the first dose if the study drug
- Patients who are breastfeeding must stop breastfeeding before the first dose of the study drug and not restart till 8 week after the last drug intake.
- Written informed consent before inclusion according to the International Conference on Harmonisation good clinical practice (ICH GCP) and national/local regulations
Exclusion Criteria:
- Life expectancy < 3 months
- Participation in another interventional study within the last 30 days
- Known hypersensitivity against a part of the study drug
- Pregnancy or breastfeeding
- HIV infection oder active hepatitis B/C
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Niclosamid
Patients receive 2 g niclosamide orally per day until progression or toxicity
|
2 g per day orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: At 4 months
|
defined as the time from patient inclusion to the date of progression
|
At 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: From date of randomization until the date of death, assessed up to 2 years
|
defined as the time from patient inclusion to the date of death or date of last follow-up news (censured data)
|
From date of randomization until the date of death, assessed up to 2 years
|
Time to progression
Time Frame: From date of randomization until the date of first documented progression, assessed up to 2 years
|
Progression according to RECIST
|
From date of randomization until the date of first documented progression, assessed up to 2 years
|
Disease control rate
Time Frame: From date of randomization, assessed up to 2 years
|
remission + partial remission + stable disease
|
From date of randomization, assessed up to 2 years
|
Number of Adverse Events > grade 2 toxicities according to NCI Common Toxicity Criteria for Adverse Effects v 4.03
Time Frame: From date of randomization, assessed up to 1 months after end ot therapy
|
number of adverse events > grade 2 toxicities according to NCI Common Toxicity Criteria for Adverse Effects v 4.03
|
From date of randomization, assessed up to 1 months after end ot therapy
|
Number of Serious Adverse Events
Time Frame: From date of randomization, assessed up to 1 months after end ot therapy
|
number of serious adverse events
|
From date of randomization, assessed up to 1 months after end ot therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2015
Primary Completion (Anticipated)
December 1, 2019
Study Completion (Anticipated)
August 1, 2020
Study Registration Dates
First Submitted
July 30, 2015
First Submitted That Met QC Criteria
August 6, 2015
First Posted (Estimate)
August 11, 2015
Study Record Updates
Last Update Posted (Actual)
September 12, 2018
Last Update Submitted That Met QC Criteria
September 11, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Anti-Infective Agents
- Antiparasitic Agents
- Antinematodal Agents
- Anthelmintics
- Antiplatyhelmintic Agents
- Anticestodal Agents
- Niclosamide
Other Study ID Numbers
- CCCC-mCRC-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
Clinical Trials on Niclosamide
-
University of BaghdadRecruitingCovid-19 | SARS PneumoniaIraq
-
TFF Pharmaceuticals, Inc.Completed
-
Imuneks Farma ilac San. Tic. A.S.Unknown
-
Charité Research Organisation GmbHBayerTerminated
-
Yonsei UniversityRecruiting
-
First Wave Bio, Inc.TerminatedUlcerative Colitis | Ulcerative Proctitis | Ulcerative ProctosigmoiditisItaly
-
National Institute of Allergy and Infectious Diseases...Terminated
-
First Wave BioPharma, Inc.Active, not recruitingCovid19United States, Ukraine, India